PROPANC BIOPHARMA, INC. (PPCB) Operating cash flow 2017–2026
PROPANC BIOPHARMA, INC. (PPCB) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$5.7MFY2026 · since FY2017: -$2.1M → -$5.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$5.7M | -1302.5% |
| FY2025 | -$405,168 | +56.7% |
| FY2024 | -$935,118 | +15.4% |
| FY2023 | -$1.1M | +23.0% |
| FY2022 | -$1.4M | -25.4% |
| FY2021 | -$1.1M | +38.1% |
| FY2020 | -$1.8M | +10.2% |
| FY2019 | -$2.1M | +5.4% |
| FY2018 | -$2.2M | -6.2% |
| FY2017 | -$2.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PPCB financial trends
PPCB RevenuePPCB Net incomePPCB Net marginPPCB Gross profitPPCB Gross marginPPCB Operating incomePPCB Operating marginPPCB Free cash flowPPCB Capital expendituresPPCB Return on equityPPCB Stock buybacksPPCB Dividends paidPPCB Total assetsPPCB Total liabilitiesPPCB Shareholders’ equityPPCB overview →